Maxpro Capital Acquisition (JMAC) Competitors $5.87 +0.05 (+0.86%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. GLUE, ALT, AURA, CADL, ABEO, INBX, TNXP, ALDX, RNAC, and IVAShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Monte Rosa Therapeutics (GLUE), Altimmune (ALT), Aura Biosciences (AURA), Candel Therapeutics (CADL), Abeona Therapeutics (ABEO), Inhibrx Biosciences (INBX), Tonix Pharmaceuticals (TNXP), Aldeyra Therapeutics (ALDX), Cartesian Therapeutics (RNAC), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Monte Rosa Therapeutics Altimmune Aura Biosciences Candel Therapeutics Abeona Therapeutics Inhibrx Biosciences Tonix Pharmaceuticals Aldeyra Therapeutics Cartesian Therapeutics Inventiva Maxpro Capital Acquisition (NASDAQ:JMAC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Do institutionals & insiders have more ownership in JMAC or GLUE? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, JMAC or GLUE? Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Does the media prefer JMAC or GLUE? In the previous week, Maxpro Capital Acquisition had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 1 mentions for Maxpro Capital Acquisition and 0 mentions for Monte Rosa Therapeutics. Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Monte Rosa Therapeutics'average media sentiment score. Company Overall Sentiment Maxpro Capital Acquisition Neutral Monte Rosa Therapeutics Neutral Do analysts prefer JMAC or GLUE? Monte Rosa Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 217.46%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings and valuation, JMAC or GLUE? Maxpro Capital Acquisition has higher earnings, but lower revenue than Monte Rosa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/AMonte Rosa Therapeutics$159.49M1.86-$72.70M$0.0860.38 Is JMAC or GLUE more profitable? Monte Rosa Therapeutics has a net margin of 3.86% compared to Maxpro Capital Acquisition's net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 2.65% beat Maxpro Capital Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Monte Rosa Therapeutics 3.86%2.65%1.65% SummaryMonte Rosa Therapeutics beats Maxpro Capital Acquisition on 9 of the 11 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$78.82M$206.73M$2.55B$9.45BDividend YieldN/A3.27%2.62%4.14%P/E RatioN/A1.9222.2124.33Price / SalesN/A559.5284.3179.11Price / CashN/A115.7726.9427.20Price / BookN/A8.9639.235.84Net IncomeN/A-$11.33M$28.61M$264.73M7 Day Performance-7.85%-1.67%-1.03%-1.04%1 Month Performance-4.40%-2.96%-0.09%6.05%1 Year Performance-45.70%48.11%14.88%23.78% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$5.87+0.9%N/A+3,289.1%$78.82MN/A0.002,021GLUEMonte Rosa Therapeutics1.2665 of 5 stars$5.96+5.3%$15.33+157.3%+21.7%$348.15M$75.62M74.5190ALTAltimmune1.8912 of 5 stars$4.29+2.1%$18.20+324.2%-40.3%$340.65M$20K-3.4050Upcoming EarningsAURAAura Biosciences2.1087 of 5 stars$7.00+3.4%$22.00+214.3%-28.5%$340.32MN/A-3.6850News CoverageCADLCandel Therapeutics2.3021 of 5 stars$6.96+4.3%$22.00+216.1%+16.6%$334.18M$120K-5.1960News CoverageUpcoming EarningsABEOAbeona Therapeutics3.8668 of 5 stars$6.71+2.9%$19.25+186.9%+36.6%$333.54M$3.50M-5.2890Upcoming EarningsINBXInhibrx Biosciences1.1456 of 5 stars$23.20+1.5%N/A+53.2%$330.92M$200K0.20166News CoverageUpcoming EarningsTNXPTonix Pharmaceuticals3.3294 of 5 stars$45.52+1.7%$70.00+53.8%-6.9%$329.24M$10.04M-0.0250ALDXAldeyra Therapeutics1.4254 of 5 stars$5.53+3.2%$9.50+71.8%+44.5%$321.04MN/A-5.7010Upcoming EarningsRNACCartesian Therapeutics2.0485 of 5 stars$13.39+9.9%$40.00+198.7%-13.3%$316.12M$38.91M-0.2564News CoveragePositive NewsUpcoming EarningsIVAInventiva2.7423 of 5 stars$3.32+0.6%$10.40+213.3%+42.7%$315.69M$9.95M0.00100Short Interest ↑Gap Down Related Companies and Tools Related Companies GLUE Competitors ALT Competitors AURA Competitors CADL Competitors ABEO Competitors INBX Competitors TNXP Competitors ALDX Competitors RNAC Competitors IVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
